In this proof-of-concept trial, we assessed the impact of two different dosing frequencies of 5-day cycles of IL-2 treatment (every 4 weeks and every 2 weeks) on peripheral Treg populations, plasma inflammatory mediators, CSF AD-related biomarkers, and cognitive and functional endpoints. This evidence concerns the gene IL2 and Alzheimer disease.